13D Filing: OrbiMed Advisors and Scpharmaceuticals Inc (SCPH)

Page 3 of 12

Page 3 of 12 – SEC Filing

SCHEDULE 13D
CUSIP No.  810648105
Page 3 of 13 Pages
1
NAME OF REPORTING PERSONS
OrbiMed Capital GP VI LLC
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a)
(b)
3
SEC USE ONLY
4
SOURCE OF FUNDS (See Instructions)
AF
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
6
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
7
SOLE VOTING POWER
0
8
SHARED VOTING POWER
3,409,865
9
SOLE DISPOSITIVE POWER
0
10
SHARED DISPOSITIVE POWER
3,409,865
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,409,865
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(See Instructions)
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
18.43%*
14
TYPE OF REPORTING PERSON (See Instructions)
OO
_______________________
* This percentage is calculated based upon 18,505,119 Shares (as defined below) outstanding of scPharmaceuticals Inc. (the “Issuer”), as set forth in the Issuer’s Prospectus on Form 424B4 filed with the Securities and Exchange Commission on November 17, 2017, and after giving effect to the additional 894,968 Shares issued and sold by the Issuer to the underwriters pursuant to the underwriters’ option.

Follow Scpharmaceuticals Inc.

Page 3 of 12